AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03222648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Responsive Exercise Training
Description: Twice weekly, 8 week structured responsive exercise training programme. Protocol used the same as that used in previous EMPOWER Trial (Loughney et al. 2016)
Study NCT03222648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Continuation of usual care
Study NCT00338065 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postural change
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
Study NCT00338065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural change
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
Study NCT00338065 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water drinking
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
Study NCT00338065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water drinking
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
Study NCT00421551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
Study NCT00421551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
Study NCT00421551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
Study NCT00421551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
Study NCT00223834 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: single session of Motivational Interviewing
Study NCT00220298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) - NebidoTM
Description: Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
Study NCT03963908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AtEase
Description: AtEase is a tailored pain self-management mobile app that tailors participant's feedback based on readiness to engage in pain self-management and preference for self-management strategies.
Study NCT03963908 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Pain Education
Description: CBT-based Education on Pain Self-Management for Veterans
Study NCT04879914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butyrate
Description: 3 cps/die 300 mg/cps
Study NCT04879914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 cps/die 300 mg/cps
Study NCT02774070 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Plain X-ray
Description: antero-posterior, lateral neutral, flexion, extension and open-mouth views
Study NCT02774070 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging sagittal T1W,T2W and STIR, axial T1W and coronal T2W and post contrast sagittal and axial sequences
Study NCT04355351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: blood sampling done on hospital staff without sars-coV-2 symptoms
Study NCT04355351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: additional blood tubes
Description: Additionnal blood tube taken during the classical blood sampling in hospital
Study NCT03749564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMT
Description: The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort.
Study NCT04483960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Nafamostat Mesilate
Description: Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
Study NCT04483960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Enoxaparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h.
Study NCT04483960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Arm Closed) Enoxaparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h.
Study NCT03749564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activation Exercises
Description: Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
Study NCT03749564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilizing Exercises
Description: Mobilizing exercises include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
Study NCT03749564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended SMT
Description: Additional 6 SMT sessions provided
Study NCT03837912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reported safety experiences fed back to PC providers
Description: The intervention will involve three key stages: a) Measurement: Patients will be invited to complete the Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC) questionnaire using a tablet-computer. b) Feedback: Using a bespoke online tool, the information will be processed and presented to each centre in the form of a Feedback Report, which will offer comparisons with other centres along with a set of recommendations for addressing the problems identified. c) Action planning and change: centres will form an Action Planning Team, which will be responsible for analyzing the report, considering which area(s) should be improved, and developing, implementing and monitoring an action plan to address the safety problems identified.
Study NCT02251990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir
Description: FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.
Study NCT02251990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
Study NCT03626597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine Pregnancy Test
Description: CHV will provide all participants with in-person urine pregnancy tests (UPTs)
Study NCT03626597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHV-based post-test counseling & referral
Description: CHVs will provide in-person post-test counseling \& referral to care
Study NCT04483960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Dalteparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h.
Study NCT04483960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Arm Closed) Dalteparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h.
Study NCT04483960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Tinzaparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia).
Study NCT03626597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone-based post-test counseling & referral
Description: Participants will call/SMS or be called/SMSed for phone-based counseling \& referral to care
Study NCT01792180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility feedback device with use of instruction book
Description: Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
Study NCT04872764 — intervention group
Intervention type: OTHER
Intervention: duration of hospitalization, mortality rate
Description: duration of hospitalization, mortality rates of patients hospitalised for COVID-19 evaluated and compared in patients with and without acute kidney injury.
Study NCT03071055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: intravitreal injection
Study NCT03071055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Injection [Lucentis]
Description: intravitreal injection
Study NCT01342874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Inositol
Description: inositol exposure in early GDM
Study NCT04204629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601 40mg
Description: Single dosing of HIP1601 40mg, PO
Study NCT01187693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: shoe lift
Description: shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
Study NCT03608930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable Polypectomy Snare,JHY-SD-23-230-30-A1
Description: The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation.
Study NCT02303184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg CLS-TA
Description: 40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
Study NCT02303184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: suprachoroidal sham procedure
Study NCT02303184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVT aflibercept
Description: 2 mg intravitreal injection of aflibercept
Study NCT02303184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVT aflibercept
Description: 2 mg intravitreal injection of aflibercept
Study NCT03401684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient Minds
Description: The program is designed: 1) to decrease the risk of developing a stress disorder or other mental illnesses due to workplace incidents and/or unhealthy stress; 2) to mitigate the negative impacts of mental illness and trauma through early recognition and early intervention; 3) to support the public while on the frontline; and 4) to improve the psychological health of fire staff while cultivating resilience and enhancing quality of life.
Study NCT01967732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS 2.2
Description: Single use of the Tobacco Heating System 2.2 (THS 2.2)
Study NCT01967732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Single use of subject's own conventional cigarette (CC)
Study NCT01967732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NNS
Description: Single administration of 1 mg of nicotine
Study NCT00701038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auto adjusting bi-level positive airway pressure device
Description: auto adjusting bi-level positive airway pressure device is provided for treatment of obstructive sleep apnea.
Study NCT01760850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Engage in the Esperanza y Vida educational information session for breast and cervical cancer
Study NCT01760850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Engage in an educational information session for diabetes
Study NCT01760850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01760850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03536000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography using the aCMQ-Strain method
Description: Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation
Study NCT03598413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
Study NCT02008721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGCG as putative neuroprotective agent
Description: Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
Study NCT02008721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02652988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active-tDCS
Description: Active home-based tDCS applied at home.
Study NCT02652988 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS
Description: Sham home-based tDCS applied at home.
Study NCT00935376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education Program
Description: Treatment as usual.
Study NCT00935376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging Program
Description: Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
Study NCT00935376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Program
Description: Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
Study NCT00232492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo males
Description: Intravenous saline bolus (Placebo-control) males
Study NCT02410512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
Description: Atezolizumab will be administered intravenously.
Study NCT00232492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,1 mg/kg males
Description: 0,1 mg/kg ketamine iv bolus males
Study NCT00232492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,3 mg/kg males
Description: 0,3 mg/kg ketamine iv bolus males
Study NCT04483960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Arm Closed) Tinzaparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia).
Study NCT04483960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (Arm Never Opened) Hyperimmune globulin
Description: 2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation. Three vials will have approximately 10500 AU of neutralising antibodies, equivalent to approximately 200mL of convalescent plasma
Study NCT00232492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,5 mg/kg males
Description: 0,5 mg/kg ketamine iv bolus males
Study NCT00232492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo females
Description: Intravenous saline bolus (Placebo-control) females
Study NCT00232492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,1 mg/kg females
Description: 0,1 mg/kg iv bolus ketamine females
Study NCT04483960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-Ritonavir
Description: The dose of nirmatrelvir-ritonavir is dependent on renal function. Participants will receive 100mg BD of Ritonavir and either 150mg BD (if eGFR 30-59 mL/min/1.73m2) or 300mg BD (eGFR = 60 mL/min/1.73m2) of Nirmatrelvir. Investigators are advised to consider withholding treatment if participant's eGFR \< 30 mL/min/1.73m2.
Study NCT00232492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,3 mg/kg females
Description: 0,3 mg/kg iv bolus ketamine females
Study NCT00232492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,5 mg/kg females
Description: 0,5 mg/kg iv bolus ketamine females
Study NCT00762320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Kaletra tablets
Description: Lopinavir/Ritonavir tablets 100mg/25mg
Study NCT02712034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAT + A-CHESS
Description: Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:~1. Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.~2. The latest information about addiction and recovery support, monitoring prompts, and peer and family support.~3. Advice on where to go for help and on how to make the best use of health and human services; and~4. A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.~5. A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects).